10-K: Edesa Biotech Reports Strong EB05 Phase 3 Results, Raises Capital

Edesa Biotech announced positive Phase 3 results for its ARDS drug candidate EB05 and secured significant equity financing, but faces ongoing losses and a going concern warning.

Summary

• Reported a net loss of $7.2 million for the fiscal year ended September 30, 2025, compared to $6.2 million in the prior year.
• Accumulated deficit reached $65.9 million as of September 30, 2025.
• Research and development (R&D) expenses increased by $0.8 million to $3.7 million in FY2025, driven by EB06 manufacturing and EB05 Phase 3 completion/US government study supply.
• General and administrative (G&A) expenses increased by $0.1 million to $4.2 million in FY2025, primarily due to non-cash share-based compensation.
• Grant income increased to $0.8 million in FY2025 from $0.7 million in FY2024, reflecting increased reimbursements under the 2023 SIF Agreement.
• Cash and cash equivalents stood at $10.8 million as of September 30, 2025, with a working capital surplus of $10.4 million.
• Net cash used in operating activities was $7.3 million in FY2025, up from $4.9 million in FY2024.
• Net cash provided by financing activities was $17.0 million in FY2025, primarily from Series B-1 and Series A-1 preferred share placements and the HCW ATM.
• Subsequent to September 30, 2025, an additional $3.4 million in net proceeds was raised from the sale of 1,177,568 common shares under the HCW ATM.
• The company has 8,333,823 common shares, 150 Series A-1 Shares, and 834 Series B-1 Shares outstanding as of December 12, 2025.
• EB05 (paridiprubart) met primary and secondary endpoints with statistical significance in a truncated Phase 3 clinical study for Acute Respiratory Distress Syndrome (ARDS), showing a 13% absolute improvement in survival at 28 days (39% vs 52% for placebo, p<0.001) and 60 days (46% vs 59% for placebo, p=0.003).
• EB05 also demonstrated a 41% higher relative rate of clinical improvement (no longer requiring IMV/organ support) at Day 28.
• EB06 (anti-CXCL10 mAb) for vitiligo has Health Canada approval for a Phase 2 study, with FDA discussions ongoing and enrollment anticipated by mid-2026.
• EB01 (daniluromer cream) for Allergic Contact Dermatitis (ACD) is Phase 3-ready and at the partnering stage.
• The 2023 SIF Agreement with the Government of Canada, providing up to C$23 million in partially repayable funding for the EB05 program, was amended to extend the project completion date to December 31, 2028, and defer conditional repayment to 2032.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the positive Phase 3 clinical trial results for EB05 are a significant achievement and the company has successfully raised capital, the explicit 'going concern' warning and the need for substantial additional funding to continue operations beyond the next fiscal year introduce considerable financial uncertainty and risk. The increase in net loss and cash used in operations also points to ongoing financial challenges.

Positives

• EB05 (paridiprubart) met primary and secondary endpoints with statistical significance in a Phase 3 clinical study for ARDS, demonstrating clinically meaningful improvement in survival and recovery.
• EB05 showed a 13% absolute improvement in survival at both 28 days (39% vs 52% for placebo, p<0.001) and 60 days (46% vs 59% for placebo, p=0.003) compared to placebo.
• Patients treated with EB05 demonstrated a 41% higher relative rate of clinical improvement at Day 28.
• EB05 was selected for a U.S. government-funded Phase 2 platform study by BARDA, validating its potential.
• Secured significant financing in FY2025, including $15.0 million gross from Series B-1 Preferred Shares and $1.54 million from Series A-1 Preferred Shares and Warrants.
• Received C$23 million in partially repayable funding from the Government of Canada's Strategic Innovation Fund (SIF) for the EB05 program, with C$5.75 million non-repayable.
• The SIF agreement for EB05 was amended to extend the project completion date to December 31, 2028, and defer conditional repayment to 2032, providing more operational runway.
• EB06 has received regulatory approval from Health Canada to conduct a Phase 2 proof-of-concept study in vitiligo patients.
• EB06 has demonstrated a favorable safety and tolerability profile in three previous clinical studies involving 65 healthy volunteers and non-vitiligo subjects.
• EB01 is a Phase 3-ready asset for moderate-to-severe chronic Allergic Contact Dermatitis, positioning it for potential partnering.

Negatives

• Incurred a net loss of $7.2 million for the fiscal year ended September 30, 2025, and an accumulated deficit of $65.9 million.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern, requiring additional funding or delays in development programs.
• Cash and cash equivalents at September 30, 2025, along with subsequent ATM proceeds and SIF reimbursements, may not be sufficient to fund operating expenses through the end of fiscal 2026 without delaying the EB06 program or raising additional capital.
• The Phase 3 study for EB05 was truncated, with enrollment discontinued early for business reasons, which could raise questions about the completeness of the data or future regulatory pathways.
• The company has no products approved for commercial sale and has a limited operating history, making future success uncertain.
• The issuance of preferred shares and warrants, and potential future equity raises, will cause dilution to existing common shareholders.
• The common shares rank junior to preferred shares in the event of liquidation, dissolution, or winding-up.
• The company is exposed to foreign exchange risk due to operations in Canada, which could impact operating results when translated to U.S. dollars.

Risks

• Inability to obtain substantial additional funding to finance operations through regulatory approval of product candidates, potentially forcing delays, reductions, or elimination of product development programs.
• Heavy dependence on the success of drug product candidates; failure to obtain regulatory approval or commercialize them, or significant delays, would materially harm the business.
• Reliance on information technology, with risks of failure, inadequacy, interruption, or cybersecurity incidents harming business operations.
• Uncertainty regarding the success of novel sPLA2, anti-TLR4, or anti-CXCL10 drugs, as none have been successfully commercialized to date, and potential for unknown adverse side effects.
• Even if a product candidate receives marketing approval, it may fail to achieve sufficient market acceptance by physicians, patients, and third-party payors.
• Inability to establish sales and marketing capabilities or enter into agreements with third parties for commercialization.
• Potential for unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives to harm the business.
• Substantial competition from larger pharmaceutical and biotechnology companies with greater financial and commercial resources.
• Dependence on third parties for manufacturing, including optimization, technology transfers, and scaling up, which could lead to insufficient quantities or unacceptable costs.
• Complexity and risks associated with manufacturing monoclonal antibody candidates, potentially increasing costs and limiting supply.
• Reliance on third parties to conduct clinical trials, with risks of unsatisfactory performance or failure to meet deadlines.
• The marketing approval process is expensive, time-consuming, and uncertain; delays or failure to obtain approvals would materially impair revenue generation.
• Terms of approvals and ongoing regulation may limit how products are manufactured and marketed, requiring substantial resources for compliance.
• Inability to obtain or maintain patent protection for licensed technology and products, or insufficient scope of protection, could allow competitors to commercialize similar products.
• High concentration of common share ownership among directors, executive officers, and certain other holders, potentially preventing other shareholders from influencing corporate decisions and leading to conflicts of interest.
• Failure to meet Nasdaq Capital Market listing requirements could lead to delisting, adversely affecting market liquidity and access to capital markets.
• Changes in the U.S. political and regulatory environment could affect the availability of government funding, impacting product development.
• Potential requirement to repay government grants (e.g., SIF funding) if contractual obligations, covenants, or milestones are not met.
• Exposure to risks related to currency exchange rates, particularly between the Canadian dollar and the U.S. dollar, affecting operating results upon translation.
• Risk of product liability lawsuits related to clinical trials and commercial sales, potentially incurring substantial liabilities.
• Increasing use of social media platforms could give rise to liability, data security breaches, or reputational damage.

Future Outlook

The company anticipates initiating enrollment for its EB06 Phase 2 study for vitiligo by mid-2026, with topline results potentially available within 9 to 12 months following U.S. regulatory clearance. It plans to pursue additional uses for paridiprubart (EB05) in chronic diseases and is evaluating the timing for the next steps in its EB07 program for pulmonary fibrosis. The company expects to continue incurring significant operating losses and will need to raise additional capital or reduce operating expenses to fund operations beyond fiscal 2026, with a strategy to seek public and private partners for Phase 3 clinical testing and scale-up.

Management Comments

• We believe that the strength of our technologies and our drug development capabilities have been validated by our favorable clinical data, our multiple arrangements with third parties to develop and commercialize their clinical-stage drug candidates, more than C$37 million in competitive government grant and funding awards, and selection for a U.S. government-funded clinical study by experts from BARDA, CDC, DoD, FDA and NIH.
• By initially targeting large markets that have significant unmet medical needs, we believe that we can drive adoption of new products and improve our competitive position.
• Our goal is to obtain regulatory approval and commercialize multiple clinical assets in our pipeline. We focus on disease indications that we believe have clear regulatory pathways and interest from potential licensing or development partners.
• Given the high capital requirement for pivotal clinical studies, our preferred strategy is to seek public and private partners for Phase 3 clinical testing and scale-up.
• We believe that EB06 has a number of anticipated advantages compared to other treatments available and under development for vitiligo, including addressing both adaptive and innate immune systems, treating both lesional and non-lesional skin, systemic therapy for larger body surface areas, less frequent administration, and a safer, more effective option.
• We anticipate initiating recruitment for the EB06 Phase 2 study by midyear 2026, subject to regulatory approval.
• We anticipate topline results for the EB06 Phase 2 study could be available within as few as 9 to 12 months following regulatory clearance in the U.S.
• We are currently exploring development and commercialization partnerships for paridiprubart (EB05) as well as expedited regulatory pathways that may be available in certain jurisdictions.
• Management has concluded that substantial doubt exists about our ability to continue as a going concern. We will need to raise additional capital and/or reduce our operating expenses to support the Company’s operations for at least the next 12 months.

Industry Context

Edesa Biotech operates in the highly competitive biopharmaceutical industry, focusing on inflammatory and immune-related diseases. Its pipeline includes novel monoclonal antibodies and compounds targeting large underserved markets like vitiligo and ARDS, which currently have limited treatment options. The company's strategy of in-licensing promising candidates and seeking partnerships for later-stage development aligns with common industry practices to manage high capital requirements. The selection of EB05 for a U.S. government-funded platform study by BARDA highlights a broader industry trend towards public-private collaborations for threat-agnostic therapeutics, especially in respiratory conditions. The competitive landscape includes major pharmaceutical and smaller biotechnology companies, many with greater resources, necessitating strong intellectual property and differentiated efficacy/safety profiles for Edesa's candidates to succeed.

Comparison to Industry Standards

• EB05's Phase 3 results for ARDS, showing a 13% absolute improvement in survival at 28 and 60 days, are significant in a disease with high mortality and limited treatment options. This compares favorably to the general lack of highly effective therapies for moderate to severe ARDS, where current standards of care often focus on supportive measures.
• The 41% higher relative rate of clinical improvement for EB05 patients at Day 28 suggests a meaningful impact on patient recovery, which could differentiate it from existing or developing therapies from competitors like Aqualung Therapeutics, Eli Lilly, InflaRx, and Regeneron Pharmaceuticals.
• For vitiligo, EB06's mechanism targeting CXCL10 aims to address both adaptive and innate immune responses, potentially offering a more comprehensive treatment than the currently FDA-approved JAK inhibitor cream (ruxolitinib) from Incyte Corporation, which carries increased risks of serious infections and malignancies. The systemic approach of EB06 also contrasts with topical treatments.
• EB01 for Allergic Contact Dermatitis (ACD) is positioned as a potential first-in-class topical non-steroidal anti-inflammatory compound. Its Phase 3-ready status and mechanism of inhibiting sPLA2 could offer a differentiated approach compared to competitors such as Aclaris Therapeutics, Dermavant Sciences, and Leo Pharma, which may focus on different pathways or existing steroid-based treatments.
• The company's reliance on third-party CMOs for manufacturing is a standard practice for many clinical-stage biopharmaceutical companies, allowing them to conserve capital and focus on R&D, but also introduces supply chain risks common in the industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings or claims outside the ordinary course of business. However, it may be involved in legal proceedings, claims, and litigation arising in the ordinary course of business, including contract disputes, employment matters, and intellectual property disputes.

Related Party Transactions

• Lease agreement for executive offices with 1968160 Ontario Inc., an entity affiliated with Dr. Nijhawan (CEO), with rents of approximately $76,000 in FY2025 and $78,000 in FY2024.
• Credit Agreement with PN MPC, an entity controlled by Dr. Nijhawan, for a $10.0 million revolving credit facility (Credit Limit of $3.5 million), which was terminated in October 2024 without any funds borrowed or termination penalties.
• Series A-1 Purchase Agreement (October 30, 2024) with Pardeep Nijhawan Medicine Professional Corporation (controlled by Dr. Nijhawan) for the purchase of 150 Series A-1 Preferred Shares and Warrants for an aggregate price of $1,540,819.
• Series B-1 Purchase Agreement (February 12, 2025) involved purchases by Dr. Pardeep Nijhawan (100 Series B-1 Preferred Shares for $1.0 million), Patrick Marshall (41,666 common shares for $80,000), and Carlo Sistilli (10,416 common shares for $20,000), all of whom are directors.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution from future equity raises due to ongoing funding needs and the 'going concern' warning. The issuance of preferred shares (Series A-1 and B-1) with senior preference in liquidation and conversion rights could dilute common shareholders' interests. Positive clinical data for EB05 could increase long-term value if commercialized successfully.
• **Employees:** The company expects to expand its capabilities and recruit additional qualified personnel, indicating potential growth opportunities. However, the 'going concern' warning could create uncertainty regarding job security if funding is not secured.
• **Customers/Patients:** Positive Phase 3 results for EB05 in ARDS and ongoing development of EB06 for vitiligo and EB01 for ACD offer hope for new treatment options in areas with unmet medical needs. Delays in development due to funding issues could impact patient access to these potential therapies.
• **Suppliers/Creditors:** The 'going concern' warning and reliance on third-party manufacturers and service providers introduce risk for suppliers and creditors, as the company's ability to meet future financial commitments is uncertain without additional funding. The SIF agreement's conditional repayment terms provide some clarity for government funding.
• **Regulatory Authorities:** The company's compliance with FDA, Health Canada, and other regulatory requirements is critical for product development and approval. Delays in clinical trials or manufacturing could impact regulatory timelines.

Next Steps

• Initiate engineering and clinical-grade (GMP) manufacturing runs for EB06 in the coming weeks, with data submission to the FDA upon completion.
• Initiate enrollment for the Phase 2 proof-of-concept study of EB06 in moderate-to-severe nonsegmental vitiligo patients by midyear 2026, subject to regulatory approval.
• Continue discussions with the U.S. Food and Drug Administration (FDA) for the EB06 Phase 2 study.
• Seek public and private partners for Phase 3 clinical testing and scale-up of product candidates, particularly given high capital requirements.
• Evaluate opportunities to apply for expedited regulatory review and orphan drug programs for product candidates.
• Pursue additional uses for paridiprubart (EB05) in chronic diseases.
• Evaluate the timing for the next steps in the EB07 program for the treatment of pulmonary fibrosis, subject to funding, regulatory approvals, drug manufacturing, and clinical site activation.
• Identify, evaluate, and potentially obtain rights to and develop additional clinical assets across various stages of development, focusing on inflammatory and immune-related diseases.
• Seek additional financing through equity offerings, licensing, collaboration or similar arrangements, grants, and debt financings to fund operations and meet obligations.
• Engage in discussions with various CMOs regarding long-term supply agreements for future clinical studies and potential commercialization of product candidates.

Key Dates

Recommendation

The filing presents a mixed bag of significant positive clinical developments and serious financial concerns. The strong Phase 3 results for EB05 in ARDS are a major positive, demonstrating clinically meaningful improvements in survival and recovery, which could be a significant value driver. The ongoing U.S. government-funded study and Canadian grant funding for EB05 further validate its potential. However, the explicit 'substantial doubt about its ability to continue as a going concern' is a critical red flag. The company's current cash position, even with recent raises, is insufficient to fund operations for a full year without delaying key programs or raising more capital. This indicates a high probability of further dilution for existing shareholders. While the clinical pipeline shows promise, the financial instability and the continuous need for capital raises create significant risk. A 'hold' recommendation is appropriate, acknowledging the strong clinical upside while cautioning investors about the severe liquidity and going concern risks that could lead to substantial share price volatility and potential impairment of investment.

Keywords

Biopharmaceutical, Inflammatory Diseases, Immune-Related Diseases, EB05, Paridiprubart, ARDS, Acute Respiratory Distress Syndrome, EB06, Vitiligo, CXCL10, EB01, Allergic Contact Dermatitis, Daniluromer, Clinical Trials, Phase 3 Results, SEC Filing, 10-K, Biotech, Drug Development, Monoclonal Antibody, Host-Directed Therapeutics, Nasdaq, Capital Raise, Going Concern, Intellectual Property, Government Grants, Canada, FDA, Health Canada, BARDA